NetScientific plc's (LON:NSCI) portfolio company Glycotest, has been granted a Japanese patent for its core technology for the early detection of life threatening liver disease.
The patent joins five others previously granted across Australia, US and Japan, covering the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and diseases.
The group said it soon expects to announce positive developments in the patent protection of the proprietary assay technology required to measure these novel biomarkers.
Glycotest is a private liver disease diagnostics platform commercialising novel clinical laboratory testing services to detect liver cancers and diseases, such as fibrosis-cirrhosis.
Chief executive Lawrence Cohen said the group's intellectual property portfolio along with outstanding clinical results achieved to date had potential to form the base of what it expected to be a very strong company in liver disease diagnostics.
"The Glycotest patent portfolio is becoming substantial and we expect more good news in the coming year regarding our intellectual property position," he said.